LDL particle size and reactive oxygen metabolites in dyslipidemic patients

International Journal of Preventive Medicine

Volumn 3, Issue 3, 2012, Pages 160-166

  Kotani, Kazuhiko ^a,b   Tsuzaki, Kokoro ^a   Taniguchi, Nobuyuki ^b   Sakane, Naoki ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

d ROMs test; Hyperlipidemia; Mean LDL particle size; Oxidative stress; Small dense LDL

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARTICLE SIZE; RISK FACTOR; SEX DIFFERENCE;

EID: 84858609804     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Franco M Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. Am J Med 2011;124:95-102.
2. LaRosa JC, Gotto AM Jr. Past, present, and future standards for management of dyslipidemia. Am J Med 2004;116(Suppl 6A):S3-8.
3. Ferguson EE Jr. Preventing, stopping, or reversing coronary artery disease - triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment. Dis Mon 2000;46:421-503.
4. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006;17: 412-7.
5. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006;99:1-14.
6. Chapman MJ, Guérin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998;19(Suppl A):A24-30.
7. Lee W, Min WK, Chun S, Jang S, Kim JQ, Lee DH, et al. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem 2003;36: 657-61.
8. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 2007;37:715-23.
9. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in International Journal of Preventive Medicine, Vol 3, No 3, March 2012 diabetes. Clin Chem Lab Med 2003;41:1144-9.
10. Stephens JW, Khanolkar MP, Bain SC. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 2009;202:321-9.
11. Iamele L, Fiocchi R, Vernocchi A. Evaluation of an automated spectrophotometric assay for reactive oxygen metabolites in serum. Clin Chem Lab Med 2002; 40: 673-6.
12. Vassalle C. An easy and reliable automated method to estimate oxidative stress in the clinical setting. Methods Mol Biol 2008;477:31-9.
13. Kotani K, Sakane N, Tsuzaki K, Matsuoka Y, Sano Y, Hamada T, et al. Lifestyles and oxidative stress in type 2 diabetic patients. Scand J Clin Lab Invest 2008;68: 516-8.
14. Hirose H, Kawabe H, Komiya N, Saito I. Relations between serum reactive oxygen metabolites (ROMs) and various inflammatory and metabolic parameters in a Japanese population. J Atheroscler Thromb 2009;16:77-82.
15. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:155-8.
16. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987-92.
17. Tsuzaki K, Kotani K, Fujiwara S, Sano Y, Matsuoka Y, Domichi M, et al. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with increased small dense low-density lipoprotein in a rural Japanese population: The Mima study. Metabolism 2007;56:1689-93.
18. Howard BV. Insulin resistance and lipid metabolism Am J Cardiol 1999;84: J28-32.
19. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56.
20. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: The disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005;3:254-67.
21. Nikkilä M, Pitkäjärvi T, Koivula T, Solakivi T, Lehtimäki T, Laippala P, et al. Women have a larger and less atherogenic low density lipoprotein particle size than men. Atherosclerosis 1996;119:181-90.
22. Bittner V. Perspectives on dyslipidemia and coronary heart disease in women: An update. Curr Opin Cardiol 2006;21:602-7.
23. Stan S, Levy E, Delvin EE, Hanley JA, Lamarche B, O'Loughlin J, et al. Distribution of LDL particle size in a population-based sample of children and adolescents and relationship with other cardiovascular risk factors. Clin Chem 2005;51:1192-200.